These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Nguyen TT; Gin T; Nicholls K; Low M; Galanos J; Crawford A Clin Exp Ophthalmol; 2005 Apr; 33(2):164-8. PubMed ID: 15807825 [TBL] [Abstract][Full Text] [Related]
9. Retinal hyperreflective foci in Fabry disease. Atiskova Y; Rassuli R; Koehn AF; Golsari A; Wagenfeld L; du Moulin M; Muschol N; Dulz S Orphanet J Rare Dis; 2019 Dec; 14(1):296. PubMed ID: 31878969 [TBL] [Abstract][Full Text] [Related]
10. Quantitative Analysis of Conjunctival and Retinal Vessels in Fabry Disease. Sodi A; Lenzetti C; Bacherini D; Finocchio L; Verdina T; Borg I; Cipollini F; Patwary FU; Tanini I; Zoppetti C; Rizzo S; Virgili G J Ophthalmol; 2019; 2019():4696429. PubMed ID: 31093369 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive clinical evaluation of a large Spanish family with Anderson-Fabry disease, novel GLA mutation and severe cardiac phenotype. San Román-Monserrat I; Moreno-Flores V; López-Cuenca D; Rodríguez-González-Herrero E; Guillén-Navarro E; Rodríguez-González-Herrero B; Alegría-Fernández M; Poza-Cisneros G; Piñero-Fernández JA; Sornichero-Martínez J; Gimeno-Blanes JR Med Clin (Barc); 2014 Jun; 142(11):497-504. PubMed ID: 24679964 [TBL] [Abstract][Full Text] [Related]
13. Correlation between interleukin-6 promoter and C-reactive protein (CRP) polymorphisms and CRP levels with the Mainz Severity Score Index for Fabry disease. Altarescu G; Chicco G; Whybra C; Delgado-Sanchez S; Sharon N; Beck M; Elstein D J Inherit Metab Dis; 2008 Feb; 31(1):117-23. PubMed ID: 18172744 [TBL] [Abstract][Full Text] [Related]
14. Ocular signs correlate well with disease severity and genotype in Fabry disease. Pitz S; Kalkum G; Arash L; Karabul N; Sodi A; Larroque S; Beck M; Gal A PLoS One; 2015; 10(3):e0120814. PubMed ID: 25781336 [TBL] [Abstract][Full Text] [Related]
15. Rats deficient in α-galactosidase A develop ocular manifestations of Fabry disease. Miller JJ; Aoki K; Reid CA; Tiemeyer M; Dahms NM; Kassem IS Sci Rep; 2019 Jun; 9(1):9392. PubMed ID: 31253878 [TBL] [Abstract][Full Text] [Related]
16. Visual outcome, ocular findings, and visual quality of life in patients with Fabry disease. Nilsson M; Kolagari HT; Epstein D; Samolov B; Olsson M; Naess K; Oscarson M; Teaer Fahnehjelm K Ophthalmic Genet; 2022 Dec; 43(6):841-849. PubMed ID: 36325813 [TBL] [Abstract][Full Text] [Related]
17. Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients. Orssaud C; Dufier J; Germain D Ophthalmic Genet; 2003 Sep; 24(3):129-39. PubMed ID: 12868031 [TBL] [Abstract][Full Text] [Related]
18. Ophthalmological consequences of cyanotic congenital heart disease: vascular parameters and nerve fibre layer. Cordina R; Leaney J; Golzan M; Grieve S; Celermajer DS; Graham SL Clin Exp Ophthalmol; 2015 Mar; 43(2):115-23. PubMed ID: 25077803 [TBL] [Abstract][Full Text] [Related]
19. Measuring retinal vessel tortuosity in 10-year-old children: validation of the Computer-Assisted Image Analysis of the Retina (CAIAR) program. Owen CG; Rudnicka AR; Mullen R; Barman SA; Monekosso D; Whincup PH; Ng J; Paterson C Invest Ophthalmol Vis Sci; 2009 May; 50(5):2004-10. PubMed ID: 19324866 [TBL] [Abstract][Full Text] [Related]
20. Japanese patients with Fabry disease predominantly showing cardiac and neurological manifestation with novel missense mutation: R220P. Fukutomi M; Tanaka N; Uchinoumi H; Kanemoto M; Nakao F; Yamada J; Kamei T; Takenaka T; Fujii T J Cardiol; 2013 Jul; 62(1):63-9. PubMed ID: 23608164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]